Linzagolix
Linzagolix is an oral hormonal medication used to manage moderate-to-severe symptoms of uterine fibroids and, in certain markets, endometriosis-associated pain in premenopausal women. It belongs to the gonadotropin-releasing hormone (GnRH) receptor antagonist class and works by reversibly suppressing pituitary GnRH signalling, reducing ovarian oestrogen and progesterone production. It is available as oral tablets, with dosage and use depending on the approved indication and whether add-back hormone therapy is prescribed. Common side effects include hot flushes, headache, reduced libido, and changes in menstrual bleeding. Important precautions include reduced bone mineral density, possible mood changes, and the need to assess pregnancy status before treatment, as it is not intended for use during pregnancy. Linzagolix should be prescribed by a gynaecologist, with treatment duration and bone-health monitoring tailored to the patient.
Linzagolix was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Linzagolix, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Linzagolix from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Linzagolix, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
